10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Wednesday, July 16, 2008

3 solid picks to enrich your lives:-

1)Scripscan:Glenmark Pharmaceuticals
Duration:6-9 months.
Traded in:NSE-Bse

Story:At the end of FY07, the company had 13 products in the US market and 36 ANDAs pending approval.These will help sustain its growth in the US market.The company has acquired seven pharmaceutical brands in Poland from Iceland-based Actavis and its affiliate Biovena for an undisclosed sum.The acquisition will give Glenmark an entry point into Poland and apart from opening up newer geographies, it will allow the company to replicate its domestic product portfolio in the region.Glenmark estimates sales of $15 million from the seven brands for 2008-09 with a 20 per cent growth in 2009-10.The changing business mix will also help improve its margins, going forward.The company is expected to deliver an EPS of Rs 52 for FY09.I am quite bullish on the company and this is one of the few pharma stocks which i like a lot.One of the best and safest pharma dose to prove a world of good for your portfolio.

2)Scripscan:-SAAG RR Infra Ltd
Duration:12-15 months

Story:-SAAG RR Infra Ltd is engaged in execution of infrastructure projects like water and sewer works and construction of specialised buildings (industrial, commercial and residential), roads and oil & gas pipeline construction and has positioned itself to take advantage of the growing demand in the oil & gas sector. The company has recently bagged a huge order of 288crs from ONGC for its charter hire of offshore modular workover rig 'SAAG Pacific' and for charter hire of offshore modular workover rig 'SAAG Saffron' to be executed over the next 3years.The company reported a revenue of about 66crs in all over fiscal 07-08.These order alone covers the sales by more than 4 times and gives a robust revenue visibility going foreward.The company has also has won projects from prestigious public sector and MNC clients including ISRO, NTPC, ICMR, BEML, HPCL, CMWSSB, B Braun Medical India and Degremont.The company is currently executing projects for puravankara projects,hiranandani realtors and mantri developers which are multi million dollar development projects in real estate.The company has been very aggresive in acquiring companies and if the sources are to be beleived then it has lined up few more major acquisitions in the coming few months.The company hasnt been an institutional fancy but there are news of research head of brokerages and mfs being in active talks with the management.Once gets covered may just go beyond reach.SAAG has been long overlooked in the bourses and virtually it never had a run over the last 3 years bull run.With these latest developments the company is sure to buzz a lot.A solid company to go for.

3)Scripscan:-Karuturi Global Ltd
Duration:12-15 months.
Traded in:Nse-Bse

Story:Karuturi Global is the world's largest producer of roses, cultivating 585 million stems per annum.It has over a decade of experience in rose cultivation with operations in Ethiopia, Kenya and India.The growth of an organised retail industry in the country is currently in a nascent stage of development and that will lead to a robust growth for cut-rose producers.The global supply-demand mismatch is considered to be positive for rose producers. Rise in per capita income and strong demand during festivals and Valentine's Day are fuelling huge flower consumption in India.The Indian floriculture sector is expected to grow by 40% each year (significantly higher than the global average) and almost 85% of the demand is estimated to be from roses.All these factors are expected to catapult karuturi in the top league.The revenues are expected to clock a 38 per cent CAGR over FY08-FY10 to Rs 770 crore with operating profit CAGR of 40 per cent to Rs 280 crore and a profit after tax CAGR of 52 per cent to Rs 240 crore.At present price of 23 the company is quoting at less than 6 times its fy10 earnings.Considering the huge potential of the company,karuturi is a must have.

I can be reached

No comments:

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner